Sequential Organ Failure Assessment (SOFA) Score-Based Factors Predict Early Mortality in High-Risk Patients with Living Donor Liver Transplant

Hao-Chien Hung*
Chih-Hsin Shen*
Chen-Fang Lee
Ssu-Min Cheng
Wei-Chen Lee

* Hao-Chien Hung and Chih-Hsin Shen contributed to this manuscript equally

Corresponding Author: Chen-Fang Lee, e-mail: chenfanglee@gmail.com

Source of support: Departmental sources

Background: Patients with a Sequential Organ Failure Assessment (SOFA) score >7 on post-transplant day (POD) 7 have been reported to have a higher risk of short-term mortality after living donor liver transplant (LDLT). We sought to identify factors that were associated with early mortality in this high-risk population.

Material/Methods: A total of 102 patients with a high SOFA score (>7) on POD 7 were enrolled, of which 72 (70.6%) were assigned to the survivor group, and the other 30 (29.4%) patients were assigned to the non-survivor group according to post-transplant 3-month results. Demographics, clinical data, operative parameters, and individual SOFA component scores were collected. Independent risk factors for 3-month mortality were identified by multivariate logistic regression analysis using backward elimination procedures.

Results: Of 102 high SOFA score patients, the 3-month mortality rate after LDLT in our study was 29.4%. Four independent risk factors were indicative for early death: graft-to-recipient weight ratio (GRWR) <0.8 (hazard ratio [HR]=3.00; 95% CI=1.05-8.09; P=0.041), longer warm ischemia time (HR=37.84; 95% CI=1.63-880.77; P=0.024), high liver component of the SOFA score, and cardiovascular component of the SOFA score (liver component: HR=10.39; 95% CI=1.77-60.89; P=0.009 and cardiovascular component: HR=13.34; 95% CI=2.22-80.12; P=0.005).

Conclusions: In conclusion, 3-month mortality among patients with high SOFA score on POD 7 is associated with multiple independent risk factors, including smaller GRWR, longer warm ischemia time, and higher category of liver and cardiovascular component of SOFA score. By recognizing high-risk patients earlier, the LDLT outcomes may be improved by timely intensive therapies.

Keywords: Liver Transplantation • Risk Factors • Survival Analysis

Abbreviations: SOFA – Sequential Organ Failure Assessment; POD – post-operative day; LT – liver transplant; LDLT – living donor liver transplantation; GRWR – graft-to-recipient weight ratio; HR – hazard ratio; CI – confidence interval; MELD – model for end-stage liver disease; ICU – Intensive Care Unit; CNS – central nervous system

Full-text PDF: https://www.annalsoftransplantation.com/abstract/index/idArt/931045
Background

Liver transplantation (LT) remains the optimal treatment for patients with advanced chronic liver disease, acute decompensated liver failure, and hepatocellular carcinoma [1]. Despite great improvement in surgical techniques and progress in managing allograft and critical care [2,3], early vital organs failure remains a major obstacle while managing transplant patients.

Several studies had searched for possible risk factors affecting early mortality after LT [4,5]. However, most of these studies focused on the entire population rather than a particular group with extremely high risk.

The Sequential Organ Failure Assessment (SOFA) [6] score was initially developed to describe and detect organ failure in sepsis settings and has become one of the most comprehensive tools to predict early outcomes in various intensive care units (ICU) [7,8]. The SOFA score [6] was traditionally calculated by a sum of corresponding scores from 6 components – respiratory, coagulation, cardiovascular, liver, renal, and central nervous system (CNS) – with a 0 to 4 scale, shown in Supplementary Table 1. Our group previously reported that patients with a SOFA [6] score >7 on post-transplant day 7 are considered to have a higher risk of short-term mortality after LT [9]. The 3-month mortality rate in this high-risk population was found to be up to 67.5% [7]. This conclusion has been examined to discriminate between survivors and non-survivors [10]. Nevertheless, some patients with high post-transplant SOFA scores still can recover from a critical condition, and the most important factors remains inconclusive.

In this study we tried to validate the SOFA model for a larger cohort in the last 10 years. We aimed to identify decisive factors associated with mortality in the high-risk population of living donor liver transplantation (LDLT) to improve the overall survival.

Material and Methods

Study Population and Data Collection

A total of 527 consecutive LDLT cases, during the period between January 2010 and March 2019, were retrospectively reviewed. Exclusion criteria were: pediatric patients (<18 years old, n=3), lack of essential SOFA information (n=5), and post-transplant day 7 SOFA score ≤7 (n=417). Subsequently, we enrolled 102 patients with high POD 7 SOFA scores (>7). This study was approved by our Institutional Review Board (No. 202001325B0). All patients fit the standard indication for the necessity of liver transplantation. Associated clinical information, laboratory data, and SOFA scores on POD 7 were documented. Preoperative data included recipient and donor age, sex, body mass index, ABO compatibility between the recipient and the donor, model for end-stage liver disease (MELD) score, Child-Pugh class, primary etiology of liver disease, and relevant medical history. We also collected intraoperative data on ischemia time, total operation time, ascites amount, blood loss, and graft-to -recipient weight ratio (GRWR). The survival period was defined as the time from liver transplant until death due to any causes and was censored on the last follow-up date on which the patient was alive. Our primary outcome was post-transplant 3-month survival, and we further divided all patients into survivor (n=72) and non-survivor groups (n=30).

SOFA Score Calculation and SOFA Components Dichotomy

We simplified these SOFA categories by dichotomizing each organ system score by an optimal cut-off value, which was determined by receiver operating characteristic curve to predict post-transplant 3-month mortality. Each SOFA category was dichotomized by cut-off values: 0 for cardiovascular, 2 for coagulation, 1 for renal, 2 for liver, 2 for respiration, and 0 for CNS.

LDLT Programs and Post-transplant Care

Before getting approval for performing a liver transplant, routine work-up must be completed, including liver and vascular images, echocardiogram, pulmonary function test, a variety of urine and blood tests (to determine blood type, clotting function, biochemical studies, and serology screening), and consultations with the transplant team members (hepatologist, surgeon, psychologist, transplant coordinator, social worker, and other specialists, as dictated by particular needs). In addition, patients need to receive pre-liver transplant HLA compatibility screening and lymphocyte cross-matching, and a goal of anti-blood type isoagglutinin titers equal to or less than 1: 64 is desired while performing ABO-incompatible LDLT. Two different pre-transplant rituximab regimens are given according to the anti-A and -B isoagglutinin titers before transplantation, and extra plasmapheresis or plasma exchange was given for patients who failed to reach the goal before receiving transplantation. The details and results of our pre-transplant preparation and post-transplant immunosuppression were illustrated in a previously published article [11].

We performed LDLT using standard technique, as our previous publications described [12,13], and we do not routinely remove the spleen. Regarding prophylactic antibiotics, our routine program suggests a third-generation cephalosporin prescription for uncomplicated patients with a lower MELD score (≤20). For patients with a threshold MELD score greater than 20 or who have a complex medical condition (eg, tense ascites, older recipient age, massive intraoperative blood loss), the combination of carbapenem, vancomycin, and echinocandins is administrated [14].
Regarding post-transplant care, ICU care is indispensable to observe and check the progress of vitals and graft condition. The length of ICU stay varies according to individual's medical stability, and it usually ranges from 5 to 10 days. An extension of ICU stay is indispensable when a patient has organ failure in one or more organs in the first week, including: neurologic or respiratory failure requiring ventilator dependence, persistent shock status, acute deterioration of kidney function causing fluid/electrolyte imbalance requiring renal replacement therapy, uncontrolled or new bleeding episode, any medical emergency that needs a second operation, or any combination of these factors.

### Statistics

The independent t test was used to determine relationships between continuous variables (expressed by mean±standard deviations), while Pearson’s chi-square test was used for categorical variables (numbers and percentages). Variable with a P value <0.100 in univariate logistic regression modeling was required as a prior condition before being entered into multivariate analysis to identify independent risk factors for 3-month mortality after transplant. Survival comparisons were constructed with the Kaplan-Meier method with log-rank test. All P values are 2-sided and a level ≤ 0.05 was considered statistically significant. We performed all analyses by using SPSS Statistics version 24.0 (SPSS, Inc., Chicago, IL, USA).

### Results

#### Characteristics of Enrolled Patients

Table 1 shows recipient and donor characteristics, surgery-related factors, and total SOFA score and corresponding components on POD 7 of 102 high-risk LDLT cases. The mean age was 53.3±9.5 and 33.1±9.2 years for recipients and donors, respectively. Most of the recipients were male (n=73, 71.6%), while the sex ratio of donors was about equal (n=47, 46.1%). The leading etiology was viral hepatitis (hepatitis B virus: n=65, 63.7%; hepatitis C virus: n=30, 29.4%), and 22 (21.6%) patients had hepatocellular carcinoma. There were 39 (38.2%) patients with a history of alcohol abuse. The mean MELD score was 27.7±15.9 and 10.0±6.8 for recipients and donors, respectively. Most of the recipients were 53.3±9.5 and 33.1±9.2 years for recipients and donors, respectively. Most of the recipients were male (n=73, 71.6%), while the sex ratio of donors was about equal (n=47, 46.1%). The leading etiology was viral hepatitis (hepatitis B virus: n=65, 63.7%; hepatitis C virus: n=30, 29.4%), and 22 (21.6%) patients had hepatocellular carcinoma. There were 39 (38.2%) patients with a history of alcohol abuse. The mean MELD score was 27.7±15.9 and 10.0±6.8 for recipients and donors, respectively. Most of the recipients were male (n=73, 71.6%), while the sex ratio of donors was about equal (n=47, 46.1%).

In univariate analysis, we analyzed all available clinical factors, and 5 factors (older donor age, smaller GRWR, longer warm ischemia time, and higher liver and cardiovascular components) were subsequently considered as potential risk factors (P<0.100) associated with 3-month mortality after transplant, as shown in Table 3. These potential risk factors were entered into multivariate analysis, showing that GRWR <0.8 (hazard ratio [HR]=3.00; 95% confidence interval [CI]=1.05-8.09; P=0.041) and higher categorized liver component of SOFA score (HR=10.39; 95% CI=1.77-60.89; P=0.009), cardiovascular component of SOFA score (HR=13.34; 95% CI=2.22-80.12; P=0.005), and longer warm ischemia time (HR=37.84; 95% CI=1.63-880.77;
The Association Between High SOFA Components and Adverse Events

It is relatively common to have a high-risk liver component score (>2); for total serum bilirubin > 6 mg/dL, there were 72 cases among that fulfilled the criterion. After excluding patients who were actually having a fair recovery from pre-transplant hyperbilirubinemia (n=30), the remaining 42 patients experienced a variety of conditions that deteriorated their liver...

Table 1. Demographic characteristics of 102 patients with post-transplant day 7 SOFA score >7.

| Factors                  | Median or number | Mean±SD     | Range       |
|--------------------------|------------------|-------------|-------------|
| General information      |                  |             |             |
| Recipient age, years     | 54.0             | 53.3±9.5    | 28.1-68.8   |
| Recipient BMI, kg/m²     | 24.2             | 24.6±3.7    | 18.2-40.0   |
| Recipient sex, Male      | 73 (71.6%)       | 33.1±9.2    | 18.5-59.7   |
| Donor age, years         | 31.8             | 33.1±9.2    | 18.5-59.7   |
| Donor BMI, kg/m²         | 22.9             | 23.1±2.9    | 17.5-30.8   |
| Donor sex, Male          | 47 (46.1%)       | 24.9±10.5   | 8-40        |
| MELD score               | 24               | 24.9±10.5   | 8-40        |
| HBV infection            | 65 (63.7%)       | 0.95±0.24   | 0.54-1.74   |
| HCV infection            | 30 (29.4%)       | 2.9±0.7     | 0-4         |
| Alcohol use              | 39 (38.2%)       | 1.6±1.0     | 0-4         |
| HCC                      | 22 (21.6%)       | 1.3±1.2     | 0-4         |
| Ascites, mL              | 2825             | 1110.8±4101.3 | 0-13 500   |
| GRWR, %                  | 0.92             | 0.95±0.24   | 0.54-1.74   |
| Blood loss, mL           | 2475             | 2962.6±229.0 | 250-14 500 |
| Cold ischemia time, minutes | 30             | 45.8±44.6   | 8-246       |
| Warm ischemia time, minutes | 36             | 37.1±9.6    | 15-64       |
| Operation time, minutes  | 634              | 653.5±1110  | 460-1219    |
| ICU stay length, days    | 19               | 28.2±20.9   | 4-90        |
| SOFA on POD 7            |                  |             |             |
| Cardiovascular component | 0                | 0.2±0.5     | 0-3         |
| Coagulation component    | 3                | 2.9±0.7     | 0-4         |
| Respiratory component    | 2                | 1.6±1.0     | 0-4         |
| Renal component          | 1                | 1.3±1.2     | 0-4         |
| Liver component          | 3                | 3.1±1.0     | 0-4         |
| CNS component            | 0                | 0.8±1.1     | 0-4         |
| Total score              | 9                | 9.8±1.9     | 8-16        |

SOFA – Sequential Organ Failure Assessment Score; SD – standard deviation; BMI – body mass index; MELD – model for end-stage liver disease; HBV – hepatitis B virus; HCV – hepatitis C virus; HCC – hepatocellular carcinoma; GRWR – graft recipient weight ratio; CNS – central nervous system; ICU – Intensive Care Unit.

P<0.024) were independent risk factors for 3-month mortality after LDLT. We compared Kaplan-Meier survival curves by numbers of risk factors a patient had (21 patients had 0 risk factors, 52 patients had 1 risk factor, 26 patients had 2 risk factors, and 3 patients had 3 risk factors; none of them had all 4 risk factors), and the group with multiple risk factors had inferior outcomes (P<0.001, Figure 4).
Figure 1. Distribution of SOFA scores on POD 7 among the enrolled population (n=102) in the current study.

Figure 2. Kaplan-Meier plot of the 3-month survival according to high and low SOFA score on POD 7 with a cut-off value of 7. There was significant survival difference (P<0.001) between the 2 groups.

Table 2. Baseline demographics and clinical characteristics of high SOFA score patients by 3-month mortality.

| Factors                        | Survivors, n=72 | Non-survivors, n=30 | P value |
|--------------------------------|-----------------|----------------------|---------|
| General information            |                 |                      |         |
| Recipient age, year-old (>60)  | 18 (25.0%)      | 11 (36.7%)           | 0.234   |
| Recipient sex (Male)           | 52 (72.2%)      | 21 (70.0%)           | 0.821   |
| Recipient BMI, kg/m²           | 24.6±3.6        | 24.6±4.0             | 0.992   |
| Donor age, year-old (>45)      | 5 (6.9%)        | 7 (23.3%)            | 0.019   |
| Donor gender (Male)            | 13 (45.8%)      | 14 (46.7%)           | 0.939   |
| Donor BMI, kg/m²               | 22.8±2.9        | 24.0±3.0             | 0.073   |
| MELD score                     | 25.6±10.2       | 23.1±11.2            | 0.279   |
| HBV infection                  | 49 (68.1%)      | 16 (53.3%)           | 0.159   |
| HCV infection                  | 22 (30.6%)      | 8 (26.7%)            | 0.694   |
| Alcohol use                    | 29 (40.3%)      | 10 (33.3%)           | 0.511   |
| HCC                            | 18 (25.0%)      | 4 (13.3%)            | 0.192   |
| Pre-transplant RFA history     | 3 (4.3%)        | 0 (0.0%)             | 0.258   |
| Abdominal operation history    | 13 (18.6%)      | 4 (13.8%)            | 0.566   |
| Child-Pugh class (B/C)         | 21/46 (29.2/63.9%) | 13/15 (43.3/50%) | 0.375   |
| Ascites, mL (>3000)            | 34 (47.2%)      | 14 (46.7%)           | 0.959   |
| Graft weight, gm               | 616.9±130.0     | 550.7±171.9          | 0.064   |
| GRWR, % (<0.8)                 | 16 (22.2%)      | 13 (43.3%)           | 0.031   |
| Blood loss, mL (>3000)         | 26 (36.1%)      | 10 (33.3%)           | 0.789   |
function. Most had various degrees of infection \(n=21\), and 6 of them were directly associated with biliary complications, and 2 were cytomegalovirus disease-related. Acute rejection occurred in 11, and more than half \(n=6\) eventually lost the graft. Vascular complications \(n=4\) (3 insufficient portal inflow and 1 hepatic venous outflow obstruction), cardiopulmonary complications \(n=3\) (2 acute myocardial infarctions and 1 cardiac arrhythmia), and massive hemorrhagic events \(n=3\) were also responsible for high liver component score (>2) on POD 7.

On the other hand, there were 11 cases with high-risk cardiovascular component scores (>0), such as hypotension with a mean arterial pressure less than 70 mmHg, and only 1 of them was directly heart-originated because of acute myocardial infarction. The rest of them were mostly due to septic shock \(n=8\), followed by hemorrhagic shock \(n=1\), and portal vein thrombosis-related graft and multiple organ failures \(n=1\).

**Causes of Death in the High-risk Population**

The causes of death are summarized in Table 4. Of the 30 deaths within 90 days after liver transplantation, 7 (23.3%) deaths were considered to be related to rejection, with the majority owing to a combination of either simultaneous or subsequent infection. A primary critical infection accounted for 15 deaths (50.0%); 8 originated from the respiratory tract, 4 were due to intraabdominal infection, 1 was associated with urinary sepsis, 1 was attributed to central nervous system infection, and the last 1 was due to catheter-associated blood stream infection. Other less common causes of death

---

**Table 2 continued.** Baseline demographics and clinical characteristics of high SOFA score patients by 3-month mortality.

| Factors | Survivors, \(n=72\) | Non-survivors, \(n=30\) | \(P\) value |
|---------|---------------------|-------------------------|-----------|
| Cold ischemia time, minutes (>60) | 14 (19.4%) | 9 (30.0%) | 0.245 |
| Warm ischemia time, minutes (>60) | 1 (1.4%) | 3 (10.0%) | 0.041 |
| OP time, minutes (>700) | 16 (22.2%) | 11 (36.7%) | 0.132 |
| SOFA on POD 7 | 9±1.5 | 10±2.2 | 0.001 |
| Cardiovascular component (>0) | 4 (5.6%) | 7 (23.3%) | 0.008 |
| Coagulation component (>2) | 57 (79.2%) | 25 (83.3%) | 0.629 |
| Respiratory component (>2) | 10 (13.9%) | 4 (13.3%) | 0.941 |
| Renal component (>1) | 44 (61.1%) | 23 (76.7%) | 0.132 |
| Liver component (>2) | 45 (62.5%) | 27 (90.0%) | 0.005 |
| CNS component (>0) | 23 (31.9%) | 14 (46.7%) | 0.159 |
| Events | | | |
| Infection | 21 (29.2%) | 15 (50.0%) | 0.045 |
| Rejection | 5 (6.9%) | 7 (23.3%) | 0.019 |
| Vascular complication | 0 (0.0%) | 4 (13.3%) | 0.002 |
| Cardiopulmonary-related | 2 (2.8%) | 2 (6.7%) | 0.357 |
| Bleeding | 2 (2.8%) | 2 (6.7%) | 0.357 |
| ICU stay length, days | 28.4±23.4 | 27.5±13.9 | 0.256 |
| Ventilator dependence* | 19 (26.4%) | 16 (53.3%) | 0.009 |

SOFA – Sequential Organ Failure Assessment Score; BMI – body mass index; MELD – model for end-stage liver disease; OP – operation; BMI – body mass index; HBV – hepatitis B virus; HCV – hepatitis C virus; HCC – hepatocellular carcinoma; RFA – radiofrequency ablation; GRWR – graft-recipient weight ratio; CNS – central nervous system. The value within parentheses indicates optimal cut-off value to predict 3-month mortality after liver transplantation. * Ventilator dependence was defined as failed weaning within 48 hours after transplant or re-intubation of endotracheal tube within 7 days after extubating.

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
were vascular complications, either portal inflow insufficiency or hepatic venous outflow obstruction (n=4, 13.3%), cardiopulmonary failure (n=2, 6.7%), and bleeding (n=2, 6.7%). Table 4 also reveals the relationship between numbers of independent risk factors (0 to 3) that individuals had and the causes of death. Although rejection and vascular complications seemed to have more risks, there was no strong correlation among SOFA scores, causes of death, and the number of independent risks.
Discussion

In the current study targeting patients with high POD 7 SOFA score (>7), already considered to be a high-risk population, we found that smaller GRWR, longer warm ischemia time, and higher category of cardiovascular and liver component of SOFA score were correlated to post-transplant short-term adverse outcomes. Interestingly, 2 factors (GRWR and warm ischemia time) outweighed some SOFA components on POD 7 except for cardiovascular and liver component of SOFA score. They can be accessed beforehand to make medical adjustment and prepare in advance for those who might be at very high risk of short-term mortality. In liver allograft recipients, it is important to predict their outcomes. The SOFA scoring scale is an objective assessment to evaluate vital system function, especially in critically ill patients [7]. A convention of GRWR <0.8% has been generally considered as a poor indicator for post-transplant liver function, and it can compromise LT outcomes [15,16]. It is evident that the length of warm ischemia time should be controlled to within 60 minutes to reduce post-transplant complications, especially acute kidney injury [17].

Several SOFA-based prediction models [9,10,18] displayed high discrimination power in predicting mortality after LT, but none paid particular attention to SOFA components and their impact or focused on these sicker patients. We believe that the essence of the SOFA score after LT is the liver component, which is also an indispensable criterion for early allograft dysfunction diagnosis [19]. Moreover, most of our 3-month mortalities were complicated with an infectious condition, which may play a role in predisposing to liver graft dysfunction or be a result of graft failure. On the other hand, the cardiovascular component of the SOFA score is a clinical indicator of circulatory function and severity of sepsis, and reflects treatment response. It is a common problem in dealing with early post-transplant infection [20,21], especially when trying to reduce the risk of rejection by increasing immunosuppressive therapy. When the inflammatory reaction is compromised by anti-rejection drugs, the microbial invasion is often in the process of spreading when revealed clinically [22]. Therefore, a thorough routine examination of patients to identify obscure infectious sources and give early interventions, such as lower immunosuppressive level and apply broad-spectrum antibiotics, is fundamental.

Elsayed et al demonstrated that the duration of ICU stay is also a significant risk factor related to early mortality after living donor liver transplantation [23]. However, in the current study, the ICU stay length between the 2 groups did not differ significantly. A possible explanation might be the relative long observation period (90 days) and high-risk patients (SOFA score >7 on POD 7) we assessed. An extension of ICU stay was common in the population we chose (mean ICU stay: 28.2 days in the current study vs 9.5 in Elsayed et al), which had a trend of needing more medical care and frequent observation of vital and graft conditions.

| Causes                      | 0 risk | 1 risk | 2 risks | 3 risks | Total |
|-----------------------------|--------|--------|---------|---------|-------|
| Infection                   | 1 (3.3%) | 8 (26.7%) | 5 (16.7%) | 1 (3.3%) | 15 (50.0%) |
| Rejection                   | 0 (0.0%) | 1 (6.7%) | 4 (13.3%) | 2 (6.7%) | 7 (23.3%) |
| Vascular complication*      | 0 (0.0%) | 0 (0.0%) | 4 (13.3%) | 0 (0.0%) | 4 (13.3%) |
| Cardiopulmonary-related**   | 0 (0.0%) | 1 (3.3%) | 1 (3.3%) | 0 (0.0%) | 2 (6.7%) |
| Bleeding***                 | 1 (3.3%) | 0 (0.0%) | 1 (3.3%) | 0 (0.0%) | 2 (6.7%) |
| Total                       | 2 (6.7%) | 10 (33.3%) | 15 (50.0%) | 3 (10.0%) | 30 (100.0%) |

SOFA score on POD 7

| SOFA score, mean±SD         | 10.0±2.8 | 11.5±2.6 | 10.6±2.1 | 10.0±1.0 | 10.8±2.2 |
| SOFA score, min. to max.    | 8-12     | 8-16     | 8-14     | 9-11     | 8-16     |

Table 4. Causes of death among non-survivors according to numbers of independent risks contained.

POD – post-operative day; SD – standard deviation; min – minimum; max – maximum. * Included 3 insufficient portal inflow and 1 hepatic venous outflow obstruction; ** included 1 acute myocardial infarction and 1 pulmonary embolism; *** both were massive gastric variceal bleeding.
Our study found that patients with multiple risk factors tend to have an inferior prognosis. Therefore, efforts are started in donor selection to avoid grafts with small GRWR and preclude complex biliary anastomoses if possible. Detailed and precise surgical planning and execution are needed to avoid unnecessary risks and long ischemia time. In post-transplant critical care, the first step is to identify the subgroup of patients who are at high risk of developing adverse outcomes in the early post-operative period. Preventing and early detection of acute allograft rejection is a major issue to address, especially in patients with infectious concerns. We believe that the adoption of a consummate LDLT protocol and reducing associated risks will help to improve transplant outcomes.

This study has several limitations. First, the retrospective nature restricted the ability to access a serial measure and to evaluate whether the reversal of organ failure helps to improve patient outcomes. Second, this research was conducted in a single tertiary medical center, and conflicts may arise from possible protocol bias between our facility and other facilities. Larger and prospective studies are required to confirm our findings.

Conclusions

In conclusion, 3-month mortality among patients with high SOFA score on POD 7 is associated with multiple independent risk factors, including smaller GRWR, longer warm ischemia time, and higher category of cardiovascular and liver component of SOFA score. By reducing risk factors in high-risk populations, the LDLT outcomes can make greater progress.

Acknowledgement

The authors gratefully acknowledge all LT team members who dedicate their best efforts in taking care of transplant patients in our hospital.

Conflicts of Interest

None.

Supplementary Data

Supplementary Table 1. The sequential organ failure assessment (SOFA) score and its components.

| SOFA score | 0 | 1 | 2 | 3 | 4 |
|------------|---|---|---|---|---|
| **Respiratory** | | | | | |
| PaO2/FiO2 | >400 | >300-<400 | >200-<300 | >100-<200, use of ventilator | ≤100, use of ventilator |
| **Coagulation** | | | | | |
| Platelets, ×10^11/mm^3 | >150 | >100-<150 | >50-<100 | >20-<50 | ≤20 |
| **Liver** | | | | | |
| Bilirubin, mg/dL | <1.2 | ≥1.2-<2.0 | ≥2.0-<6.0 | ≥6.0-<12.0 | ≥12 |
| **Cardiovascular** | | | | | |
| Hypotension, or catecholamine doses, μg/kg/min for at least one hour | MAP ≥70 mm Hg | MAP <70 mm Hg | Dopamine ≤5, or use of dobutamine | Dopamine >5, or epinephrine or norepinephrine ≤0.1 | Dopamine >15, or epinephrine or norepinephrine >0.1 |
| **CNS** | | | | | |
| Glasgow Coma Score | 15 | 13-14 | 10-12 | 6-9 | <6 |
| **Renal** | | | | | |
| Creatinine, mg/dL, or urine output | <1.2 | ≥1.2-<2.0 | ≥2.0-<3.5 | ≥3.5-<5.0, or <500 mL/day | ≥5.0, or <200 mL/day |

SOFA – Sequential Organ Failure Assessment; CNS – central nervous system; FiO2 – fractional inspired oxygen; MAP – mean arterial pressure; PaO2 – arterial oxygen tension.
References:

1. Zarrinpar A, Busuttil RW. Liver transplantation: Past, present and future. Nat Rev Gastroenterol Hepatol. 2013;10(7):434-40
2. Park GC, Song GW, Moon DB, Lee SG. A review of current status of living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5(2):107-17
3. Pillai VG, Chen CL. Living donor liver transplantation in Taiwan-challenges beyond surgery. Hepatobiliary Surg Nutr. 2016;5(2):145-50
4. Qian YB, Cheng GH, Huang JF. Multivariate regression analysis on early mortality after orthotopic liver transplantation. World J Gastroenterol. 2002;8(1):128-30
5. Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1407-32
6. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10
7. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-58
8. Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12(6):R161
9. Pan HC, Jenq CC, Lee WC, et al. Scoring short-term mortality after liver transplantation. Liver Transpl. 2010;16(2):138-46
10. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-49
11. Sawyer RG, Crabtree TD, Gleason TG, et al. Impact of solid organ transplantation and immunosuppression on fever, leukocytosis, and physiologic response during bacterial and fungal infections. Clin Transplant. 1999;13:260-65
12. Elsayed FG, Sholkamy AA, Elshazli M, et al. Comparison of different scoring systems in predicting short-term mortality after liver transplantation. Transplant Proc. 2015;47(4):1207-10